

Elder Pharmaceuticals Ltd.				
STANDALONE UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER ENDED 30th JUNE, 2011				
				(Rupees lacs)
Sr. No.	Particulars	3 months ended 30.06.2011 (Unaudited)	Corresponding 3 months ended in the previous year 30.06.2010 (Unaudited)	Previous accounting year ended 31.03.2011 (Audited)
1				
a	Net sales / Income from operations	22356.07	19108.96	83142.96
b	Other operating income	0.55	16.09	100.66
	Total Income (a + b)	22356.62	19125.05	83243.62
2	Expenditure			
a)	Increase (-) / Decrease (+) in stock in trade and work in process.	2247.24	-633.66	-3435.21
b)	Consumption of Raw Materials	3211.08	3292.63	12440.14
c)	Purchase of traded goods	4857.42	6262.18	28618.91
d)	Employees cost	2749.33	2547.03	10881.98
e)	Depreciation	729.65	494.96	2687.35
f)	Other Expenditure	4019.85	3705.81	17556.72
g)	Total	17814.57	15668.95	68749.89
3	Profit from operations before other income, interest & exceptional items	4542.05	3456.10	14493.73
4	Other income	209.34	205.91	842.80
5	Profit before interest & exceptional items	4751.39	3662.01	15336.53
6	Interest	1742.68	1373.18	5929.03
7	Profit after interest but before exceptional items	3008.71	2288.83	9407.50
8	Exceptional items (Refer note number 6 below)	137.10	100.96	500.55
9	Profit from ordinary activities before tax	2871.61	2187.87	8906.95
10	Tax expenses (Refer note number 4 below)	530.00	300.00	1766.83
11	Net profit from ordinary activities after tax but before minority interest.	2341.61	1887.87	7140.12
12	Extraordinary items	0.00	0.00	0.00
13	Net profit for the period	2341.61	1887.87	7140.12
14	Paid up equity share capital (Face value Rs.10/-)	2053.69	1885.74	2053.69
15	Reserves excluding revaluation reserves as per Balance sheet of previous accounting year	-	-	-
16	Earnings Per Share (EPS)			
a)	Basic & diluted EPS before extraordinary items for the period, for the year to date & for the previous year	11.40	10.01	35.88
b)	Basic & diluted EPS after extraordinary items for the period, for the year to date & for the previous year	11.40	10.01	35.88
17	Public shareholding			
-	Number of shares	12637837	11215678	12637837
-	Percentage of shareholding	61.54	59.48	61.54
18	Promoters & Promoter Group Shareholding			
A)	Pledged/Encumbered			
-	Number of Shares	3633150	5767659	3579150
-	Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	45.99	75.48	45.31
-	Percentage of shares (as a % of the total share capital of the company)	17.69	30.58	17.43
	B) Non-Encumbered			
-	Number of Shares	4265949	1874149	4319949
-	Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	54.01	24.52	54.69
-	Percentage of shares (as a % of total share capital of the company)	20.77	9.94	21.04
Notes:				
1) The above results were reviewed by the Audit committee and approved by the Board of Directors at their meeting held on 12th August 2011				
2) The statutory Auditors have carried out a limited review of the unaudited (provisional) financial results for the quarter ended 30th June 2011				
3) The Company operate in Pharmaceutical segment only. Hence, pursuant to accounting standard AS-17 on segment reporting, segmental information is not required to be given.				
4) Exceptional item of Rs.137.10 lacs pertains to exchange loss on quarterly installment of ECB repayment.				
5) Provision for Tax includes current tax, and deferred tax.				
6) Investor complaints: Pending at the beginning of the quarter - Nil. Received during the quarter - 10. Pending at the end of the quarter - Nil				
7) Previous years figures have been regrouped/rearranged wherever necessary.				
			For Elder Pharmaceuticals Ltd	
Place: Mumbai			J. Saxena	
Date: 12th August, 2011			Managing Director	